2025
Chemically Induced Hypertension: Antineoplastic Agents Associated with High Blood Pressure
Moss E, Shirali A. Chemically Induced Hypertension: Antineoplastic Agents Associated with High Blood Pressure. Updates In Hypertension And Cardiovascular Protection 2025, 79-91. DOI: 10.1007/978-3-031-81292-7_5.Peer-Reviewed Original ResearchVascular endothelial growth factor signal pathway inhibitorsAdverse effects of anticancer therapyEffects of anticancer therapySystemic adverse effectsTyrosine kinase inhibitorsExacerbation of hypertensionTreatment of malignanciesDevelopment of hypertensionAssociated with hypertensionDrug-drug interactionsBlood pressure monitoringSignaling pathway inhibitorsCalcineurin inhibitorsHigh blood pressureAdjuvant medicationsAntineoplastic therapyProteosome inhibitorKinase inhibitorsIncreased riskSubsequent treatmentAnticancer therapyPathway inhibitorBlood pressureAntineoplastic drugsHypertension
2023
Chemotherapy-Associated Thrombotic Microangiopathy
Aklilu A, Shirali A. Chemotherapy-Associated Thrombotic Microangiopathy. Kidney360 2023, 4: 409-422. PMID: 36706238, PMCID: PMC10103319, DOI: 10.34067/kid.0000000000000061.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyPlasma exchangePrimary atypical hemolytic uremic syndromeAtypical hemolytic uremic syndromeEnd-organ dysfunctionMicroangiopathic hemolytic anemiaSecondary thrombotic microangiopathyTherapeutic plasma exchangeTerminal complement inhibitorLarge multicenter studyHemolytic uremic syndromeRole of complementPotential treatment strategyProteinuria reductionSupportive careBlood pressureMulticenter studyTreatment courseUremic syndromeComplement inhibitionTreatment strategiesHemolytic anemiaAntiangiogenesis agentsComplement inhibitors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply